Journal of the American Society of Nephrology · 2015 · 130 citations · 24 references
Life SciencesBiochemistryNephrologyEnzymologyRenal PathophysiologyRenal Replacement TherapyEnzyme DeficienciesEnzyme InhibitionLysosomal DysfunctionLysosomal Storage DisordersRenal DiseaseClinical Outcome MeasurementDisease Severity IndexDisorderEndogenous InhibitorsEnzyme Replacement TherapyFabry DiseaseLysosomal Storage DefectsRenal Function Loss
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequences of serum-mediated agalsidase inhibition in affected patients, we determined the agalsidase inhibition status of 168 patients (68 male) with FD and compared outcomes of inhibition-positive patients with those of inhibition-negative patients. The assessment included clinical events during time on agalsidase, determination of renal and cardiac function, and evaluation of FD-related symptoms. The frequency of serum-mediated agalsidase inhibition was 40% in agalsidase-treated males. Inhibition did not depend on the compound initially used (agalsidase-α or -β). Agalsidase inhibition was associated with higher lyso-globotriaosylceramide levels and worse disease severity scores in patients. Compared with agalsidase inhibition-negative men, agalsidase inhibition-positive men showed greater left ventricular mass (P=0.02) and substantially lower renal function (difference in eGFR of about -30 ml/min per 1.73 m(2); P=0.04), which was confirmed by a longitudinal 5-year retrospective analysis. Additionally, affected patients presented more often with FD-typical symptoms, such as diarrhea, fatigue, and neuropathic pain, among others. Therefore, patients with poor clinical outcome on agalsidase should be tested for agalsidase inhibition. Future studies are warranted to determine if affected patients with FD benefit from acute reduction of anti-agalsidase antibodies or long-term immune modulation therapies to suppress agalsidase inhibition and to identify mechanisms that minimize antibody generation against agalsidase.
24
Ömer Toprak, Hüseyin Kurt, Yasin Sarı et al. · Kidney & Blood Pressure Research · 2017 · 29.7K citations · Full text
Medicine, Endocrinology, Nutrition +17
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al. · Annals of Internal Medicine · 2009 · 25.7K citations
Pharmacy, Nephrology, Physiology +12
Roberto M. Lang, Michelle Bierig, Richard B. Devereux et al. · Journal of the American Society of Echocardiography · 2005 · 11.3K citations
Kidney International Supplements · 2012 · 3.2K citations